Neil Stahl - Dec 16, 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Research and Development
Signature
/s/**Neil Stahl
Stock symbol
REGN
Transactions as of
Dec 16, 2022
Transactions value $
$0
Form type
4
Date filed
12/20/2022, 03:08 PM
Previous filing
Dec 13, 2022
Next filing
Aug 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Award $0 +1.1K +2.12% $0.00 53.1K Dec 16, 2022 Direct F1
holding REGN Common Stock 5.81K Dec 16, 2022 By 401(k) Plan
holding REGN Common Stock 4.61K Dec 16, 2022 by Spouse as Trustee

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Award $0 +4.06K $0.00 4.06K Dec 16, 2022 Common Stock 4.06K $726.53 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 16, 2024 and 50% on December 16, 2026.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.